News
HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.
4h
Asianet Newsable on MSNPfizer Stock Climbs Pre-Market On Bladder Cancer Trial Success: Retail Digests Data Ahead Of Q1 PrintPfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to ...
Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...
Novo Nordisk has launched its popular weight-loss drug Wegovy in Thailand, marking its first entry into the Southeast Asian ...
President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...
Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results